The landscape of d16HER2 splice variant expression across HER2-positive cancers
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2045-2322
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
The landscape of d16HER2 splice variant expression across HER2-positive cancers ; volume:9 ; number:1 ; day:5 ; month:3 ; year:2019 ; pages:1-12 ; date:12.2019
Scientific reports ; 9, Heft 1 (5.3.2019), 1-12, 12.2019
- Urheber
-
Volpi, Chiara Costanza
Pietrantonio, Filippo
Gloghini, Annunziata
Fucà, Giovanni
Giordano, Silvia
Corso, Simona
Pruneri, Giancarlo
Antista, Maria
Cremolini, Chiara
Fasano, Elena
Saggio, Serena
Faraci, Simona
Bartolomeo, Maria Di
Braud, Filippo de
Nicola, Massimo Di
Tagliabue, Elda
Pupa, Serenella Maria
Castagnoli, Lorenzo
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1038/s41598-019-40310-5
- URN
-
urn:nbn:de:101:1-2019032418080167335390
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:54 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Volpi, Chiara Costanza
- Pietrantonio, Filippo
- Gloghini, Annunziata
- Fucà, Giovanni
- Giordano, Silvia
- Corso, Simona
- Pruneri, Giancarlo
- Antista, Maria
- Cremolini, Chiara
- Fasano, Elena
- Saggio, Serena
- Faraci, Simona
- Bartolomeo, Maria Di
- Braud, Filippo de
- Nicola, Massimo Di
- Tagliabue, Elda
- Pupa, Serenella Maria
- Castagnoli, Lorenzo
- SpringerLink (Online service)
Ähnliche Objekte (12)
Synthetic lethality between HER2 and transaldolase in intrinsically resistant HER2-positive breast cancers
Endophilin A2 promotes HER2 internalization and sensitivity to trastuzumab-based therapy in HER2-positive breast cancers
Inhibition of the transcriptional kinase CDK7 overcomes therapeutic resistance in HER2-positive breast cancers
Triple-negative and HER2-positive breast cancers found by mammography screening show excellent prognosis
Genetic mutation profile of Chinese HER2-positive breast cancers and genetic predictors of responses to Neoadjuvant anti-HER2 therapy
Correction: Inhibition of the transcriptional kinase CDK7 overcomes therapeutic resistance in HER2-positive breast cancers
An Elaborate New Linker System Significantly Enhances the Efficacy of an HER2‐Antibody‐Drug Conjugate against Refractory HER2‐Positive Cancers
Das HER2-positive metastasierte Mammakarzinom – aktuelle Behandlungskonzepte
PYK2 promotes HER2-positive breast cancer invasion
T-cell metagene predicts a favorable prognosis in estrogen receptor-negative and HER2-positive breast cancers
T-cell metagene predicts a favorable prognosis in estrogen receptor-negative and HER2-positive breast cancers
Increased pathologic complete response are expected in HER2-positive and triple-negative locally advanced breast cancers
Synthetic lethality between HER2 and transaldolase in intrinsically resistant HER2-positive breast cancers
Endophilin A2 promotes HER2 internalization and sensitivity to trastuzumab-based therapy in HER2-positive breast cancers
Inhibition of the transcriptional kinase CDK7 overcomes therapeutic resistance in HER2-positive breast cancers
Triple-negative and HER2-positive breast cancers found by mammography screening show excellent prognosis
Genetic mutation profile of Chinese HER2-positive breast cancers and genetic predictors of responses to Neoadjuvant anti-HER2 therapy
Correction: Inhibition of the transcriptional kinase CDK7 overcomes therapeutic resistance in HER2-positive breast cancers
An Elaborate New Linker System Significantly Enhances the Efficacy of an HER2‐Antibody‐Drug Conjugate against Refractory HER2‐Positive Cancers
Das HER2-positive metastasierte Mammakarzinom – aktuelle Behandlungskonzepte
PYK2 promotes HER2-positive breast cancer invasion
T-cell metagene predicts a favorable prognosis in estrogen receptor-negative and HER2-positive breast cancers
T-cell metagene predicts a favorable prognosis in estrogen receptor-negative and HER2-positive breast cancers
Increased pathologic complete response are expected in HER2-positive and triple-negative locally advanced breast cancers
Synthetic lethality between HER2 and transaldolase in intrinsically resistant HER2-positive breast cancers
Endophilin A2 promotes HER2 internalization and sensitivity to trastuzumab-based therapy in HER2-positive breast cancers
Inhibition of the transcriptional kinase CDK7 overcomes therapeutic resistance in HER2-positive breast cancers
Triple-negative and HER2-positive breast cancers found by mammography screening show excellent prognosis
Genetic mutation profile of Chinese HER2-positive breast cancers and genetic predictors of responses to Neoadjuvant anti-HER2 therapy
Correction: Inhibition of the transcriptional kinase CDK7 overcomes therapeutic resistance in HER2-positive breast cancers
An Elaborate New Linker System Significantly Enhances the Efficacy of an HER2‐Antibody‐Drug Conjugate against Refractory HER2‐Positive Cancers
Das HER2-positive metastasierte Mammakarzinom – aktuelle Behandlungskonzepte
PYK2 promotes HER2-positive breast cancer invasion
T-cell metagene predicts a favorable prognosis in estrogen receptor-negative and HER2-positive breast cancers
T-cell metagene predicts a favorable prognosis in estrogen receptor-negative and HER2-positive breast cancers